Cargando…
Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study
BACKGROUND: Although trastuzumab (T) represents the standard of care for the adjuvant treatment of HER2‐positive early‐stage breast cancer, contrasting results are available about the cardiac toxicity associated to its use. We conducted a multiregional population‐based cohort investigation aimed to...
Autores principales: | Franchi, Matteo, Trama, Annalisa, Merlo, Ivan, Minicozzi, Pamela, Tarantini, Luigi, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Apolone, Giovanni, Corrao, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543336/ https://www.ncbi.nlm.nih.gov/pubmed/32770690 http://dx.doi.org/10.1634/theoncologist.2020-0216 |
Ejemplares similares
-
Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
por: Franchi, Matteo, et al.
Publicado: (2020) -
Bortezomib-based therapy in non-transplant multiple myeloma patients:
a retrospective cohort study from the FABIO project
por: Franchi, Matteo, et al.
Publicado: (2021) -
Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2021) -
Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
por: Hingmire, Sachin S., et al.
Publicado: (2017) -
Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)